Why Is SPYRE THERAPEUTICS I (SYRE) Stock Down Today?

Spyre Therapeutics (SYRE) fell 13.68% to $80.04 in afternoon trading on October 6, 2026, following the announcement of a $350 million public offering priced at $85.00 per share. The stock opened with a 4.8% gap down from the previous close of $92.72 and continued to decline throughout the session. The offering, which includes a 30-day option for up to $52.5 million in additional shares, triggered immediate selling pressure as investors digested the dilutive impact on existing shareholders.

What Happened

The company announced the pricing of 4,117,648 shares of common stock at $85.00 per share, with expected gross proceeds of about $350.0 million. The underwriters also have the option to purchase up to an additional 617,648 shares within 30 days. This secondary offering is intended to fund Spyre’s programs in gastroenterology, rheumatology, and dermatology. The announcement came after a recent uptrend in the stock, which had gained 9.8% over the previous eight sessions, moving from $84.18 to $92.45. The offering price of $85.00, below the recent closing price, signaled a bearish sentiment to the market.

What The Data Shows

The intraday session showed a sharp decline after the opening high of $93.00 at 8:30 AM ET. The stock hit a session low of $80.03 at 10:35 AM ET and closed near that level. Volume reached 0.9 million shares, which is 0.7 times the 3-month daily average. Over the past 30 days, sentiment has averaged 43 out of 100, with a recent seven-day average of 39, indicating a worsening outlook. Insider selling has also been notable, with nine transactions totaling $16.9 million reported in the last 90 days. Additionally, the stock printed 19 fresh 52-week lows on October 6.

What To Watch

Spyre Therapeutics has no scheduled earnings report in the near term. Investors should monitor the breadth of coverage and market reaction to the offering as the 30-day option period progresses.